ClinicalTrials.gov
public full text
Public Domain
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anti-GD2 ADC M3554 in Advanced Solid Tumors#1071849
- PRO1107 in Patients With Advanced Solid Tumors#852344
- A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors#1151326
- A Study of ADRX-0706 in Select Advanced Solid Tumors#1378107
- Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies#1381945
Record · ID 1383721
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive